Y0000674
Leflunomide for peak identification
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Leflunomide, 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C12H9F3N2O2
CAS Number:
Molecular Weight:
270.21
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
leflunomide
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F
InChI
1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChI key
VHOGYURTWQBHIL-UHFFFAOYSA-N
유전자 정보
human ... DHODH(1723)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Leflunomide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
표적 기관
Respiratory system
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Paul Bird et al.
The Journal of rheumatology, 40(3), 228-235 (2013-01-17)
To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice. The Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis (SMILE) study
Babak Baban et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 303(11), R1136-R1146 (2012-10-27)
The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with
T Adizie et al.
International journal of clinical practice, 66(9), 906-909 (2012-08-18)
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory rheumatic conditions affecting adults over the age of 50 years. Both conditions respond to initial glucocorticoid (GC) therapy. However, most patients require 12-36 months of a tapering steroid regime.
Sebastian Unizony et al.
Current opinion in rheumatology, 25(1), 3-9 (2012-11-02)
Recent advancements in the understanding of the pathogenesis of large-vessel vasculitis may broaden our currently limited therapeutic possibilities. This review summarizes the available evidence for new treatment strategies in this spectrum of diseases. Interleukin (IL) 6 appears to be an
Paul A J Russo et al.
The Annals of pharmacotherapy, 47(3), e15-e15 (2013-03-01)
To study the pharmacokinetics and pharmacogenetics of leflunomide and document its efficacy and safety in the treatment of inflammatory arthritis in a patient with end-stage renal disease (ESRD) who was on peritoneal dialysis. Therapy for a 78-year-old man with ESRD
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.